Multiplex Assay Kit for Vitamin D Receptor (VDR) ,etc. by FLIA (Flow Luminescence Immunoassay) 
NR1I1; Nuclear Receptor Subfamily 1 Group I Member 1; Calcitriol Receptor; 1,25-dihydroxyvitamin D3 receptor
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 393.00 US$ 408.00 US$ 431.00 US$ 461.00 US$ 491.00 US$ 537.00 US$ 605.00 US$ 756.00
- Quantity
Overview
Properties
- Product No.LMA475Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayEndocrinology
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Vitamin D Receptor (VDR) and the recovery rates were calculated by comparing the measured value to the expected amount of Vitamin D Receptor (VDR) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 85-93 | 88 |
| EDTA plasma(n=5) | 91-102 | 95 |
| heparin plasma(n=5) | 80-91 | 84 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vitamin D Receptor (VDR) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vitamin D Receptor (VDR) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vitamin D Receptor (VDR) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-105% | 78-91% | 83-101% | 78-102% |
| EDTA plasma(n=5) | 79-89% | 87-103% | 78-104% | 92-103% |
| heparin plasma(n=5) | 85-92% | 82-90% | 97-104% | 84-91% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:VDR) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Vitamin D Receptor (VDR) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Vitamin D Receptor (VDR) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Vitamin D Receptor (VDR) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Vitamin D Receptor (VDR) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- The vitamin D receptor: A therapeutic target for the treatment of breast cancer?Cgi: Content
- Vitamin D receptor as a target for breast cancer therapy.pubmed:28213567
- Effect of exercise on serum vitamin D and tissue vitamin Dreceptors in experimentally induced type 2 Diabetes Mellitus.pubmed:27504197
- Vitamin D supplementation attenuates oxidative stress in paraspinal skeletal muscles in patients with low back painPubmed:29143122
- Enhanced remedial effects for vitamin D3 and calcium co-supplementation against pre-existing lead nephrotoxicity in mice: The roles of renal calcium homeostatic …Pubmed: 30553018
- Seluang Fish (Rasbora Spp.) Oil Decreases Inflammatory Cytokines Via Increasing Vitamin D Level in Systemic Lupus Erythematosus
- Status of vitamin D and the associated host factors in pulmonary tuberculosis patients and their household contacts: a cross sectional studyPubmed: 31255688
- Association of Fok1 VDR polymorphism with Vitamin D and its associated molecules in pulmonary tuberculosis patients and their household contactsPubmed: 31649297
- Vitamin D Status in Dupuytren's Disease: Association with Clinical Status and Vitamin D Receptor Expression
- Betok Fish (Anabas testudineus) Oil Decreases Inflammatory Cytokine through Increasing Vitamin D Level in Rats-induced Systemic Lupus Erythematosus
- Positive Correlation between Monocyte-to-Lymphocyte Ratio and C-Reactive Protein in Vitamin D Deficient Preterm Infants with Respiratory Distress Syndrome
- Identification of SNP of VDR and VDBP gene and its Dysregulated pathway through VDR-VDBP interaction network analysis in Vitamin D deficient Infertile …